Background-Statin therapy influences not only low-density lipoprotein (LDL) cholesterol levels but also LDL-related biomarkers, including non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B, total number of LDL particles, and mean LDL particle size. Recent studies have identified many genetic loci influencing circulating lipid levels and statin-induced LDL cholesterol reduction. However, it is unknown how these genetic variants influence statininduced changes in LDL subfractions and non-HDL-C. Methods and Results-One hundred sixty candidate single-nucleotide polymorphisms for effects on circulating lipid levels or statin-induced LDL-cholesterol lowering were tested for association with response of LDL subfractions and non-HDL-C to rosuvastatin or placebo for 1 year among 7046 participants from the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Of the 51 single-nucleotide polymorphisms associated with statin response for ≥1 of the LDL subfractions or non-HDL-C, 20 single-nucleotide polymorphisms could be clustered according to effects predominantly on LDL particle size, predominantly on LDL particle number, and on apolipoprotein B but not on LDL cholesterol or non-HDL-C. Conclusions-These differential associations point to pathways of LDL response to statin therapy and possibly to mechanisms of statin-dependent cardiovascular disease risk reduction. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.
S tatin-mediated inhibition of hydroxy-3-methylglutaryl-Co-A reductase, an enzyme catalyzing the rate-limiting step in cholesterol synthesis, lowers circulating low-density lipoprotein (LDL) cholesterol primarily by inducing uptake of LDL particles (LDL-P) from plasma into peripheral tissues. 1 As a consequence, statins also affect alternative measures related to LDL-P, including levels of non-high-density lipoprotein (HDL) cholesterol (non-HDL-C), levels of apolipoprotein B (apoB), the total number of LDL-P, and the mean LDL-P size (LDL-size). 2 The responses to statin of these alternative LDL measures are somewhat but not entirely correlated with each other and with LDL cholesterol (LDL-C) and are discordant in up to a quarter of healthy individuals, 3 in the sense that statin-lowered LDL-C is not always accompanied by lower LDL-P number or apoB concentration. Thus, these alternative measures of LDL response to statin therapy are not necessarily reflected in LDL-C reduction and may have clinical relevance. Among agents targeting LDL-C lowering for prevention of incident cardiovascular disease (CVD), statin therapy seems to be especially beneficial. For example, statins may cause as much as ≥50% lowering of LDL-C, and throughout this range, there is approximately a 10% lowering of CVD risk per a 10% reduction in LDL-C. 4 By contrast, LDL-C lowering by inhibitors of Niemann-Pick protein 5 (ie, ezetemibe, via inhibition of intestinal cholesterol absorption) or cholesteryl ester transfer protein 6, 7 (CETP, via inhibition of the exchange of cholesterol and triglyceride in HDL particles and these lipids in LDL and very LDL particles), both are only somewhat less potent at lowering LDL-C than statins and are accompanied by smaller reductions in CVD risk. These findings are consistent with the hypothesis that the benefit of statin therapy is not solely induced by LDL-C lowering per se, a notion also consistent with the observed modest differences in the magnitude of residual vascular risk with statin therapy depending on which LDL-related measure is evaluated. 8 Understanding the detailed consequences of statins' effects on LDL metabolism may reveal the biological basis for the dramatic risk reduction observed in many statin trials.
To date, few if any clinical variables have been identified that distinguish among statin-induced changes in LDL-related measures. Meanwhile, recent work has demonstrated substantive genetic influence not only on circulating lipid levels [9] [10] [11] but also on statin-induced changes in LDL-C. 12 The primary aim of this study was to examine whether candidate genetic loci associated with circulating lipids that represent several different biological pathways could explain differential response of LDL-C compared with response of other LDL-related lipoprotein fractions and non-HDL-C to statin treatment. Thus, we sought in the context of a randomized placebo-controlled trial to address whether a panel of 160 single-nucleotide polymorphisms (SNPs) known from the literature to influence basal levels of conventional lipid fractions or LDL-C change with statin therapy, might be associated with statin-induced changes in non-HDL-C, apoB, LDL-P, and LDL-size and further whether there may be differential associations among these alternative LDL measures. These markers were selected for analysis on the basis that the LDL fraction is the target of statin therapy, and therefore, statin effects on these measures would be larger and more likely to be detectable than for other lipid fractions, such as HDL, which are also influenced by statin therapy but to a lesser degree. 13 As shown here, in a study of 7046 men and women of European ancestry allocated to 20 mg of rosuvastatin or placebo for a 12-month period, there were 3 groups of SNPs that were predominantly associated with statin response in 1 or a subset of lipid measures but not with the others. The groups of genes implied by the selective SNP effects seem to influence substantially different aspects of lipid metabolism and catabolism, reflecting the complexity of cholesterol transport and biosynthesis and highlighting the basis of complex statin effects that are not revealed by analysis of LDL-C response alone.
Methods

Study Population
The study population for this analysis was derived from the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER; NCT00239681) trial. JUPITER is an international, randomized, placebo-controlled evaluation of rosuvastatin (20 mg per day) conducted among men and women free of CVD with moderate-to-low LDL-C levels (<130 mg/dL) and elevated C-reactive protein levels (≥2 mg/L) at baseline. 14 Blood samples were obtained at the time of randomization and after 12 months of treatment with either placebo or rosuvastatin. Participants included in this analysis consented to procedures used in the JUPITER trial for the genetic testing of samples. All procedures and protocols in this study were approved by the Partners Human Research Committee (Institutional Review Board for Partners Healthcare on behalf of Brigham and Women's Hospital).
Genotyping and Imputation
Study participants were genotyped using the Omni 1M Quad platform and GenomeStudio version 1.6.2 (both Illumina, San Diego, CA) by the manufacturer. A total of 1 006 348 SNPs passed quality control standards as previously described. 12 In short, only a small subset of markers had poor characteristics on clustering metrics for ABrMean (intensity), cluster separation, Hardy-Weinberg equilibrium, or call frequency. These markers were visually inspected and either flagged, removed, or reclustered manually. Detailed experimental data on individual genotypes and plots for manually clustered variants are available in the study by Chasman et al. 12 SNPs were retained in the final data set if the updated clusters met quality standards and the genotyping was successful in at least 98.5% of the samples. A multidimensional scaling procedure in PLINK 15 was used to verify self-reported European ancestry; 37 participants were excluded because of discordance between self-reported ancestry and assignment of European ancestry by multidimensional scaling. A total of 33 individuals from 31 family groups were excluded in the JUPITER trial data to eliminate the first degree relatives as judged by PLINK. 15 EIGENSTRAT was used to estimate sub-European stratification and calculate principal components. 16 Approximately 6.8 million SNPs from the pilot data of the 1000 Genomes Project were imputed using MaCH version 1.0.16. 17, 18 All genotyped SNPs used for imputation either met Hardy-Weinberg equilibrium P>10 -6 or for the case of APOE (rs7412), included manual review of genotyping clusters. 12 Imputation quality scores for all candidate SNPs were >0.7 (MaCH, R 2 >0.7); imputation quality scores of the individual SNPs are provided in Table I in the Data Supplement.
Biomarker Measurement
LDL-C, non-HDL-C, apoB 100 , HDL-C, and total cholesterol were measured in a core laboratory facility at the time of randomization and after 12 months of randomized allocation to placebo or rosuvastatin treatment as previously described. 12 Non-HDL-C was calculated by subtracting HDL-C from total cholesterol measurements and captures the amount of cholesterol carried by apoB particles. LDL-P and LDL-size were determined by proton nuclear magnetic resonance (NMR) spectroscopy analysis (NMR LipoProfile3, LipoScience, Raleigh, NC) 19 and capture the total number of LDL-P and the mean size of all LDL-P, respectively.
SNP Selection
A total of 154 candidate SNPs from the published genome-wide association study (GWAS) of circulating plasma lipids from the Global Lipids Genetics Consortiumn (GLGC) 9,10 were selected for analysis ( Table IIA in the Data Supplement). When multiple SNPs mapped to the same locus and were in LD, the SNP with the most significant P value (in association with any lipid) was chosen as the locus representative (index SNP). All index SNPs that mapped to the same locus but were nevertheless not in LD were included. A proxy (rs8035382) was used for the original index SNP (rs292982) at 1 locus FRMD5 (R 2 =1; 1000 genomes) where the original index was neither genotyped nor imputed. Three SNPs were neither genotyped nor imputed and did not have any proxies available; therefore, these SNPs were excluded from analysis (rs2412710 CAPN3, rs1047891 CPS1, and rs13238203 TYW1B).
In addition, 6 candidate SNPs (rs17111584, PCSK9; rs2199936, ABCG2; rs10455872, LPA; rs12317268, SLCO1B1; rs11672123, LDLR; and rs7412 APOE) for statin-induced LDL-C reduction in the JUPITER trial 12 were included in the analysis ( Table IIB in the Data  Supplement) . Four loci (APOE, LDLR, LPA, and PCKS9) contain 2 SNPs each; however, the variants are independent of one another (R 2 <0.03 between the 2 SNPs at each of the 4 loci). A listing of all candidate SNPs can be found in Table IIC in the Data Supplement.
Analysis
Primary outcomes examined in this study were absolute change and percentage change in LDL-C, non-HDL-C, apoB, LDL-P, and LDLsize after 12 months of rosuvastatin or placebo therapy. Absolute change was calculated as the difference between the 12-month and the baseline value; and percentage change was calculated by dividing the absolute change by the baseline value, such that, for example, greater reduction in LDL-C was reflected in negative values with greater magnitude. The percentage change calculation implicitly accounts for baseline measures. Analysis of each outcome was stratified by statin-allocation arm and restricted to the 7046 participants with both baseline and 12-month lipoprotein measures, compliance with study medication based on pill counts and the absence of self-reported nontrial statin use. To assess the effect of the recruitment criteria in the JUPITER trial (LDL-C<130 mg/dL) on known lipid associations, additional analyses were performed among a combined total of 7046 participants (allocated to either rosuvastatin or placebo) for association of candidate SNPs from GLGC and baseline measures of LDL-C, non-HDL-C, apoB, LDL-P, and mean LDL-size. Spearman correlation coefficients were calculated between all baseline and change measures in ≤3534 statin-allocated participants.
To decrease the influence of extreme outliers on the change outcomes, all measures were transformed using inverse-quantile normalization, 9, 20, 21 which was carried out in the statin-and placebo-allocated arms (preserving the ranks within each allocation group). We chose to transform our data by inverse-quantile normalization because of the long right tail we observed for statin-induced absolute change in many of the examined traits; log transformation was not possible because the distributions of absolute and percentage changes include negative values. P values for association were obtained from linear regression of transformed outcome measures, whereas estimates of the genetic effects were obtained from linear regression of untransformed outcome measures, both encoding genetic information with a standard additive genetic model assuming proportionality between the number of inherited copies of the minor (ie, coded) allele and mean LDL phenotype. Thus, negative regression coefficients implied greater reduction of LDL-C, non-HDL-C, apoB, and LDL-P levels or greater reduction in the mean size of LDL-P with each additional inherited copy of the minor allele. In interaction analysis where statin-and placebo-allocated arms were combined, the values/ranking of the inverse-quantile normalized traits created within the groups would not be valid for between-group comparisons, that is, interactions. Therefore, we reverted back to the untransformed outcomes for interaction analysis. Interaction analysis was performed by introducing a standard multiplicative drug-by-SNP interaction term in the linear regression models of statin response. All regression models were adjusted for age, sex, region, and 10 principal components calculated from EIGENSTRAT.
In total, 160 candidate SNPs (full list is provided Table IIC in the Data Supplement) were evaluated for association with absolute and percentage changes in LDL-C, non-HDL-C, apoB, LDL-P, and LDLsize. Variants associated with any of the change measures among statin-allocated participants at a nominal significance level (P<0.05) were carried forward for further analysis if they were either not associated with any of the change measures among placebo-allocated participants (P≥0.05) or had drug-by-SNP interaction (P<0.1); excluding SNPs for associations with change measures among the placebo-allocated participants and excluding SNPs lacking evidence for SNP-bydrug interactions directly assured that the SNPs included were good candidates for statin response. We used complete linkage hierarchical clustering with a standard Euclidean distance metric to cluster SNP associations with change in LDL-C, non-HDL-C, apoB, LDL-P, and LDL-size among statin-allocated participants with binary encoding, specifying 1 for significant association (P<0.05) and 0 otherwise; absolute change and percentage change were clustered separately. In the complete linkage method, the distance between clusters is defined as the maximum distance between any of the individual SNP/biomarker pairs (1 in each cluster). To delineate clusters in our association results, we used the NbClust package in R 22,23 that determines credible clustering structures through consensus among 30 clustering criteria. Variance explained (R 2 ) was calculated from a regression of the inverse-quantile normalized residualized trait on each SNP.
To examine the biological connectivity and functional relationships among the genes within clusters based on SNP associations with LDL-size and LDL-P, we used Gene Relationships Among Implicated Loci tool, 24 which is based on text mining of PubMed abstracts. As recommended, to emphasize relationships that might suggest biological pathways rather than associations derived from GWAS findings, Gene Relationships Among Implicated Loci tool was run with a database derived from PubMed abstracts published before 2009, predating most GWAS findings.
Gene set enrichment analysis (GSEA) using MAGENTA 25 and R 22 was performed to test for enrichment of genes in the mean LDL-size (n=11 genes; tagged by 8 SNPs) and LDL-P number (n=11 genes; tagged by 8 SNPs) gene clusters, and 1722 predefined gene sets from Gene Ontology, BioCARTA, INGENUITY, KEGG, PANTHER, and REACTOME were used. Genes analyzed in GSEA were derived from the gene name annotations of each SNP from the published GLGC articles; if an SNP was annotated with multiple genes, 9, 10, 12 all listed genes were used in GSEA. Multiple testing was addressed by permutation with 10 000 replicates.
Results
As shown in Table III in the Data Supplement, clinical characteristics of the 7046 participants of European ancestry from the JUPITER trial who consented to genetic research had successful LDL-related biomarkers measured at baseline and 12 months and were compliant with study medications that were indistinguishable between those allocated to rosuvastatin (n=3534) and those allocated to placebo (n=3512). At 1 year, rosuvastatin reduced LDL-C by 54 mg/dL (−52%), non-HDL-C by 59 mg/dL (−45%), apoB by 43 mg/dL (−37%), LDL-P by 528 nmol/L (−7%), and LDL-size by 0.4 nm (−1.7%). Among statin-allocated participants, we observed high correlation between absolute (and percentage) changes in LDL-C, non-HDL-C, and apoB and moderate correlations between changes in these 3 measures and changes in LDL-P, but littleto-no correlation was observed between changes in LDL-size and the other LDL-related measures or non-HDL-C (pairwise correlations between all analyzed measures are provided in Table IV in the Data Supplement).
Candidate SNPs were selected from genome-wide significant associations 9,10 with ≥1 of LDL-C (n=58), HDL-C (n=74), triglycerides (n=43), total cholesterol (n=75), or statin response of LDL-C (n=6) 12 for a total of 160 unique SNPs. Of the candidates from analysis of circulating lipid levels, 64 SNPs were nominally significantly associated (P<0.05) with baseline levels of either LDL-C, non-HDL-C, apoB, LDL-P, or LDL-size (Table V in the Data Supplement) among the 7046 participants with baseline lipoprotein measures representing 132 associations of the 800 (160 SNPs×5 traits) total associations (Table V in the Data Supplement, associations meeting Bonferroni and false discovery rate thresholds). Of the 96 SNPs evaluated that did not associate with any of these LDL-related measures, 10 had been described in previous literature as being primarily associated with triglycerides, 36 with HDL-C, and 4 with both triglycerides and HDL-C. Of the remaining SNPs, 31 had previously been described in the literature as being associated with LDL-C (alone or in addition to HDL-C or triglycerides). However, not all of the candidate variants were expected to be significantly associated with baseline LDL-related measures because of a smaller size of the JUPITER sample compared with the discovery sample (7046 versus 200 000 participants 9,10 ), the primary association of some candidates with non-LDL-C lipid measures, and possibly the enrollment criteria in the JUPITER trial that required baseline LDL-C <130 mg/dL. Of the 6 candidate SNPs derived from previous analysis of LDL-C response to statin, only 1 candidate (in LDLR) was associated with LDL-C at baseline in the JUPITER trial.
All 160 SNPs were evaluated by regression for association with absolute and fractional response to statin for the 5 LDL-related lipoprotein measures (Table VIA-VID in the  Data Supplement) . SNPs with effects on statin response were selected for further examination based on the following criteria for a total of 51 SNPs: nominally significant association with 12-month change in absolute or fractional lipoprotein response among the 3534 study participants allocated to rosuvastatin (Table VIA -VID in the Data Supplement) and either no significant association with absolute or fractional response among the 3512 study participants allocated to placebo (Table  VIC and VID in the Data Supplement) or at least marginally significant interaction effect (P<0.1) for allocation to rosuvastatin versus placebo in a complementary analysis (Methods; Table VIE in the Data Supplement).
Complete linkage hierarchical clustering of the 51 SNPs selected for association with absolute change in non-HDL-C and LDL-related subfractions indicated the existence of 14 clusters (Figure; Methods) . An identical clustering procedure performed on statin-induced percentage change in non-HDL-C and LDL-related subfractions resulted in the same number of optimal clusters (n=14 clusters; Methods; Figure I in the Data Supplement). As expected, these clusters were similar but not completely identical to those identified in the absolute change results. This discrepancy is likely due to the presence of SNPs that are highly influential on circulating levels and therefore have a stronger effect on percentage change compared with absolute change. Therefore, we only focused follow-up analyses on the clusters identified by the absolute change analysis.
Among these 14 clusters identified in the absolute change results, there were 3 large clusters that were predominantly associated with a single fraction (clusters 2, 4, and 11 as indicated as clusters A, B, and C, respectively, in Figure) , 1 large cluster that was not associated with any specific LDLrelated measures nor seemed to follow a discernable pattern (cluster 1 that was not followed up in subsequent analyses), and 10 smaller clusters containing ≤3 SNPs (clusters 3, 5-10, and 12-14 also were not followed up in subsequent analyses). The first trait-specific cluster (cluster A) included 8 SNPs-rs964184 (APOA1-A5 cluster), rs3764261 (CETP), rs11694172 (FAM117B), rs4846914 (GALNT2), rs514230 (IRF2BP2), rs9686661 (MAP3K1), rs12967135 (MC4R), and rs4660293 (PABPC4)-that were associated only with statininduced response in LDL-size. The second trait-specific cluster (cluster B) included 8 SNPs-rs4420638 (APOE-C1-C2), rs7255436 (ANGPTL4), rs2277862 (ERGIC3), rs7515577 (EVI5), rs1260326 (GCKR), rs737337 (LOC55908-DOCK6), rs6759321 (RABGAP1), and rs643531 (TTC39B)-that were associated almost exclusively with statin-induced response in LDL-P. The third trait-specifc cluster (cluster C) included 4 SNPs-rs2131925 (ANGPTL3), rs11649653 (CTF1), rs2807834 (MOSC1), and rs11246602 (OR4C46)-that were associated with statin-induced response primarily in apoB and had virtually no association with statin-induced reductions in LDL-C or non-HDL-C. One branch of the top level split in the hierarchical clustering eventually leads to several small clusters (clusters, [12] [13] [14] and captures associations that were strong for statin response of LDL-C and also for the related subfractions of non-HDL-C, apoB, and LDL-P but not for LDLsize. These loci were rs2199936 (ABCG2-delta), rs10455872 (LPA-delta), rs17111584 (PCSK9-delta), rs11672123 (LDLRdelta), and rs12317268 (SLCO1B1-delta). Of note, 2 SNPs not previously identified in association with statin response of LDL-C are also present in this branch of combined clusters rs6805251 (GSK3B) and rs2293889 (TRPS1).
Bioinformatics tools were used to assess the correspondence between known biological pathways related to LDL and SNP clusters A and B, the clusters reflecting selective associations with LDL-size and LDL-P, respectively. This analysis was not done for cluster C because of the small number of SNPs in the cluster (n=4). For cluster A that is associated with change in LDL-size only, 2 genes tagged by the 8 SNPs had significant functional connections based on text mining of PubMed abstracts before 2009 (predating the main lipoprotein GWAS results) using Gene Relationships Among Implicated Loci tool (CETP [rs3764261; P=9.7×10 −3 ] and APOA5 [rs964184; P=9.0×10 −3 ] ). In addition, GSEA of the SNPs in cluster A using 1724 predetermined gene sets showed enrichment in phosphatidylcholine binding pathway (P permutation =0.03) that is related to vesicle transport; no other pathways reached statistical significance after multiple testing correction. However, 2 marginally enriched pathways (P permutation <0.1), HDL particle and cholesterol binding, are related to lipid metabolism; a list of pathways is available in Table VII in the Data Supplement. For cluster B that is related predominantly to LDL-P, none of the 11 genes tagged by the 8 index SNPs was functionally connected in Gene Relationships Among Implicated Loci analysis-the most significant result was for rs4420638 at the APOE-C1-C2 locus (P=0.06). GSEA using 1724 predetermined gene sets identified 1 marginally enriched pathway, chylomicron remnant clearance (P permutation =0.09).
Discussion
Previous genetic analysis of statin response has primarily focused on associations between LDL-C and genetic variants or SNPs either in known pathways of statin action 26 or arising from genome-wide analysis of LDL-C lowering, 12 the latter limited in statistical power by the relatively small size of suitable cohorts with genome-wide genetic data. Recently, however, GWAS of LDL-C and other lipid fractions including as many as 200 000 samples have dramatically increased the number of credible candidate variants for statin response analysis. This advance is complemented by high throughput NMR-based assays of lipoprotein subfractions that provide higher resolution lipoprotein profiles than can be inferred from standard plasma lipid measures alone. We examined the effects of 160 candidate SNPs on rosuvastatin response of LDL-C, non-HDL-C, apoB, and 2 NMR-based LDL subfraction measures during 1 year of follow-up. This investigation highlighted clearly delineated subsets of SNPs implicating clusters of genes with selective effects on LDL properties or LDL-related measures distinct from LDL-C. One of the 2 larger clusters with effects on LDL properties was selective for effects on LDL-size, whereas the other was selective for LDL-particle number. SNPs in both had essentially no effect on the rosuvastatin-induced change in LDL-C.
Several of the genes implicated for selective association with LDL-size (cluster A) may be understood in terms of known pathways regulating triglyceride levels, lipids that constitute much of the volume of LDL-P. CETP encodes CETP that exchanges triglycerides and cholesteryl esters between HDL or LDL and very LDL. 27, 28 The apoA5 protein encoded in the APOA1-APOA5 cluster is also a strong determinant of circulating triglyceride levels. 29 The candidate SNPs at these 2 genes conferred among the strongest total effects on LDL-size at baseline but exert relatively little effect on LDL-C, likely by affecting baseline triglyceride content. The exact mechanisms underlying these associations are unknown, although it may be relevant that for both loci, the alleles associated with greater LDL-size at baseline are also associated with a smaller change in size with statin allocation (Tables V, VIA, and VIB in the Data Supplement). Although MC4R locus was initially identified for association with HDL-C by the GLGC, 9, 10 this locus was also associated with triglycerides although not at genome-wide significance; and the effect at MC4R may be related to its predominant role in regulating adiposity, 30 a trait highly correlated with triglyceride levels. The mechanistic relationships of the other candidate SNPs in this cluster and the change in LDL-size with statin treatment are less clear, but both PABPC4 and GALNT2 are involved in protein expression and may act through regulation of protein rather than lipid components of LDL-P. None of the remaining SNPs (IRF2BP2, FAM117B, and MAP3K1) was significant for association with LDL-C at baseline (P>0.05) in the JUPITER trial, and only IRF2BP2 was associated with circulating LDL-C at genome-wide significance in previous analyses. 9, 10 For the most part, the associations with the cluster of determinants for rosuvastatin response of LDL-P number (LDL-P; cluster B) are not explained by a simple model of cholesterol and triglyceride regulation. The major exception to this is the APOE-C1-C2 SNP, rs4420638, which is in linkage disequilibrium with APOE4 (rs429358; R 2 =0.7). A well-studied variant in plasma lipid metabolism, APOE4, influences LDL-receptor binding, 31 but it has not previously shown evidence of association with statin-induced response in LDL-C. 12, 32 Of the remaining genes in this cluster, ANGTPL4 and GCKR have been highlighted for roles in regulation of triglyceride levels, but it is not obvious why SNPs in these genes are specifically associated with statin response of LDL-P and not, for example, mean LDL-size. GCKR's regulation is mediated through effects on glucokinase and therefore glucose metabolism, 33, 34 and these effects are manifest in association with LDL-P at baseline ( Table V in the Data Supplement ). ANGTPL4 seems to modulate the triglyceride-hydrolyzing activity of lipoprotein lipase 35, 36 and was also associated with LDL-P at baseline. Half of the candidate genes in this cluster are also associated with baseline LDL-P, which suggests that the genes that mediate the number of circulating LDL-P may also play a role in change of LDL-P number on statin therapy. However, SNPs associated with baseline LDL-P are not particularly enriched in the statin response LDL-P cluster compared with the other 3 clusters, indicating that a complex mechanism may influence statin-induced LDL-P response.
Although the gene cluster identified as cluster C (containing candidate variants from the MOSC1, ANGPTL3, CTF1, and OR4C46 genes) was most significantly associated with statin-induced changes in apoB, there was much less specificity of this cluster for change in apoB compared with the LDLsize and LDL-P clusters (clusters A and B). In part, the lack of specificity may be because of mechanisms influencing change in apoB that were not adequately captured by selecting candidate SNPs from analyses of circulating lipoproteins. We did not observe an association between the APOB SNP and statininduced change in any of the LDL-related measures analyzed (Table VIA in the Data Supplement) and only observed associations with baseline apoB and LDL-P that were marginally significant (P=0.085 and P=0.054; Table IV in the Data Supplement ). It is possible the enrollment criteria based on low LDL-C levels affected the distribution of baseline apoB and thus affected the power to detect variants associated with higher levels of apoB; there have not been any previous associations of the APOB SNP and statin-induced reduction in LDL-related measures or subfractions.
Several strengths and limitations should be considered when interpreting our results. The chief strength of the study is the unique nature of the data representing a large population-based sample with measures of lipoprotein particle concentration by NMR at baseline and after 1 year of follow-up after randomized allocation to rosuvastatin or placebo. The study also benefited from the large scale of recent genome-wide genetic analysis of conventional plasma lipid measures among ≤200 000 individuals 10 identifying 62 loci beyond the 95 that had been identified previously, 9 all combined with 6 loci with previous evidence for effects on statin response directly. 12, 26 The large number of candidates poses a risk for associations because of chance. However, this risk is offset by the strong previous evidence for roles of the candidate SNPs in lipoprotein metabolism or statin response. Moreover, our statistical criteria included verified interaction with randomized allocation to placebo. Our a priori selection of common candidate variants does not address the possibility of rare genetic variants with effects on statin-induced changes in LDL-related subfractions or non-HDL-C. Targeted sequencing of candidate genes or whole-exome sequencing would be needed to address this possibility in future investigations. We also acknowledge our lack of replication as a limitation. Ideally, we would replicate our analysis in an independent sample; however, an adequately powered sample with genotypes and the biomarkers examined in our study is currently not available. Finally, it is possible that the ascertainment in JUPITER could influence association with genetics and potentially limit generalizability; although any limitations on the population variance, as for example the LDL <130 mg/dL study entry criterion, would be expected to diminish rather than accentuate the strength of association. In addition, at baseline, the strongest GLGC SNPs remain associated with lipid fractions in the JUPITER sample (Table V in the Data Supplement ). The recently published Genomic Investigation of Statin Therapy (GIST) consortium article, 32 which did not represent trials or studies ascertained on lipoprotein level and did not include JUPITER in discovery, observed highly comparable loci for statin-induced change in LDL-C that were identified in the JUPITER trial. 12 Thus, we think that the other genetic associations we report with statin response are likely to be generalizable.
Focusing on LDL-related biomarker alternatives to LDL-C, the genetic associations reported here highlight pathways for statin response of LDL-P number, LDL-size, and apoB that differ at least in part from pathways for statin response of LDL-C. The clinical literature evaluating these alternative LDL-related measures in outcome-driven statin trials has been limited to comparing LDL-C with apoB or non-HDL-C (the amount of cholesterol carried by apoB particles). [37] [38] [39] [40] [41] [42] Meta-analysis of eligible studies suggests, for example, that achieved levels of apoB and non-HDL-C may more accurately reflect residual cardiovascular risk on statin therapy than achieved LDL-C levels. 8, 43, 44 These studies also emphasize the possibility that variation in the residual risk assessed by on-statin LDL-C levels may reflect discordance between statin responses of LDL-C and the alternative LDL-related measures. 45 It remains to be determined whether statin modification of the pathways identified by the current genetic analysis for LDL-P number and size may influence cardiovascular risk in ways that are distinguishable from statin effects on LDL-C alone.
Although the primary focus of this study was to examine differential genetic effects on statin-induced changes in LDLrelated subfractions and non-HDL-C, statin therapy is also known to beneficially influence levels of other lipoproteins, such as HDL-C. 13 To fully explore alternate pathways influencing differential CVD risk reduction by statin therapy, compared with Niemann-Pick or CETP inhibitors, future investigations would benefit from examination of genetic influences on statin-induced changes in HDL-C and other lipid biomarkers.
In conclusion, when examining LDL-related biomarker alternatives to LDL-C, we found that the genetic pathways for statin response of LDL-P number, LDL-size, and apoB only partially overlapped with pathways for statin response of LDL-C. These differences in LDL-related statin responses may provide potential therapeutic targets that could be exploited to reduce residual CV risk for individuals on statin therapy.
